Comparison of AquaBounty Technologies Inc. (AQB) and Athenex Inc. (NASDAQ:ATNX)

AquaBounty Technologies Inc. (NASDAQ:AQB) and Athenex Inc. (NASDAQ:ATNX), both competing one another are Biotechnology companies. We will compare their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AquaBounty Technologies Inc. N/A 468.85 10.62M -0.93 0.00
Athenex Inc. 82.70M 9.94 118.61M -1.29 0.00

Table 1 highlights AquaBounty Technologies Inc. and Athenex Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us AquaBounty Technologies Inc. and Athenex Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AquaBounty Technologies Inc. 0.00% -47.2% -38.8%
Athenex Inc. -143.42% -89.2% -62.5%

Liquidity

AquaBounty Technologies Inc.’s Current Ratio and Quick Ratio are 1 and 0.9 respectively. The Current Ratio and Quick Ratio of its competitor Athenex Inc. are 4.5 and 3.9 respectively. Athenex Inc. therefore has a better chance of paying off short and long-term obligations compared to AquaBounty Technologies Inc.

Insider and Institutional Ownership

AquaBounty Technologies Inc. and Athenex Inc. has shares owned by institutional investors as follows: 53.4% and 25.3%. Insiders owned roughly 6.37% of AquaBounty Technologies Inc.’s shares. Competitively, 8% are Athenex Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AquaBounty Technologies Inc. -6.02% -14.6% -20.68% -21.21% -32.37% -33.52%
Athenex Inc. -5.75% -0.08% -20.94% -25.61% -20.69% -21.64%

For the past year AquaBounty Technologies Inc.’s stock price has bigger decline than Athenex Inc.

Summary

AquaBounty Technologies Inc. beats Athenex Inc. on 6 of the 9 factors.

AquaBounty Technologies, Inc., a biotechnology company, develops and markets products to enhance productivity in aquaculture. Its lead product is the AquAdvantage Salmon, a genetically modified animal for human consumption. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was founded in 1991 and is headquartered in Maynard, Massachusetts. AquaBounty Technologies, Inc. is a subsidiary of Intrexon Corporation.

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Its Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. The company also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is based in Buffalo, New York.